New Preclinical Data Demonstrate Potential of Capsida’s IV Gene Therapy for STXBP1-DEE to Correct all Disease Manifestations

Data to be featured as oral and poster presentations at American Epilepsy Society 2024 Annual Meeting THOUSAND OAKS, Calif., Dec. 6, 2024 /PRNewswire/ — Capsida Biotherapeutics (“Capsida”) today announced new preclinical data on CAP-002, its first-in-class IV-administered next-generation…